Edwards Lifesciences Corporation | Large-cap | Healthcare
74,82 US$
-0,44 %
| Edwards Lifesciences Stock Comparison:
Edwards Lifesciences vs Abbott LaboratoriesEdwards Lifesciences vs Boston ScientificEdwards Lifesciences vs StrykerEdwards Lifesciences vs Medtronic plcEdwards Lifesciences vs DexcomEdwards Lifesciences vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 5,4B
Gross Profit 4,3B 79,46 %
Operating Income 1,5B 27,21 %
Net Income 4,2B 76,66 %
EPS (Diluted) 6,97 US$

Balance Sheet Metrics

Total Assets 13,1B
Total Liabilities 3,0B
Shareholders Equity 10,1B
Debt to Equity 0,30

Cash Flow Metrics

Operating Cash Flow 553,3M
Free Cash Flow 259,9M

Revenue & Profitability Trend

Income Statement

Metric 2024 2023 2022 2021 2020
Revenue 5,4B 6,0B 5,4B 5,2B 4,4B
Cost of Goods Sold 1,1B 1,4B 1,1B 1,2B 1,1B
Gross Profit 4,3B 4,6B 4,3B 4,0B 3,3B
Operating Expenses 2,8B 2,9B 2,5B 2,4B 2,0B
Operating Income 1,5B 1,7B 1,8B 1,6B 1,3B
Pre-tax Income 1,5B 1,6B 1,8B 1,7B 916,7M
Income Tax 152,1M 198,7M 245,5M 198,9M 93,3M
Net Income 4,2B 1,4B 1,5B 1,5B 823,4M
EPS (Diluted) 6,97 US$ 2,30 US$ 2,44 US$ 2,38 US$ 1,30 US$

Income Statement Trend

Balance Sheet

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 6,3B 4,0B 3,1B 3,2B 3,1B
Non-Current Assets 6,8B 5,3B 5,2B 5,3B 4,1B
Total Assets 13,1B 9,4B 8,3B 8,5B 7,2B
Liabilities
Current Liabilities 1,5B 1,2B 1,0B 1,0B 893,9M
Non-Current Liabilities 1,5B 1,4B 1,5B 1,6B 1,8B
Total Liabilities 3,0B 2,6B 2,5B 2,7B 2,7B
Equity
Total Shareholders Equity 10,1B 6,7B 5,8B 5,8B 4,6B

Balance Sheet Composition

Cash Flow Statement

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 4,2B 1,4B 1,5B 1,5B 823,4M
Operating Cash Flow 553,3M 1,1B 1,2B 1,8B 833,5M
Investing Activities
Capital Expenditures - - - - -
Investing Cash Flow 2,6B 440,1M 517,1M -1,4B -123,8M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow -1,2B -880,9M -1,7B -514,9M -627,4M
Free Cash Flow 259,9M 629,5M 953,4M 1,4B 647,0M

Cash Flow Trend

Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 31,05
Forward P/E 30,67
Price to Book 4,35
Price to Sales 7,98
PEG Ratio 30,67

Profitability Ratios

Profit Margin 75,71 %
Operating Margin 29,02 %
Return on Equity 16,51 %
Return on Assets 8,42 %

Financial Health

Current Ratio 4,45
Debt to Equity 6,86
Beta 1,12

Per Share Data

EPS (TTM) 2,42 US$
Book Value per Share 17,28 US$
Revenue per Share 9,30 US$

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
ew 44,1B 31,05 4,35 16,51 % 75,71 % 6,86
Abbott Laboratories 232,9B 17,38 4,77 30,65 % 31,89 % 27,09
Boston Scientific 147,6B 72,80 6,64 9,50 % 11,58 % 52,16
Stryker 144,2B 50,99 6,89 14,26 % 12,31 % 82,92
Medtronic plc 111,9B 24,17 2,33 9,51 % 13,90 % 59,09
Dexcom 32,1B 61,65 14,18 23,72 % 12,90 % 113,97

Financial data is updated regularly. All figures are in the company's reporting currency.